Eurofins: TruGraf Contracted With Humana for In-network Coverage of Medicare Kidney Transplant Patients
07 Luglio 2021 - 6:00PM
Business Wire
Regulatory News:
Eurofins
(Paris:ERF):
Eurofins Transplant Genomics,
Inc. (“TGI”), the transplant rejection diagnostics company
committed to improving organ transplant outcomes worldwide, is
excited to announce the first national in-network contract for
TruGraf, its proprietary gene expression test for subclinical acute
rejection. Humana, a leading health care company that offers a wide
range of insurance products and health and wellness services, will
offer in-network coverage for the TruGraf blood gene expression
test to its Medicare kidney transplant patients, effective August
1, 2021.
TruGraf is the first blood
gene expression test approved by CMS/Medicare. TruGraf offers the
earliest possible detection of "silent" subclinical acute rejection
in kidney transplant patients with stable kidney function before
organ injury and chronic acute rejection begins. This novel
biomarker test offers transplant patients a non-invasive option for
otherwise painful biopsy procedures, leading to detection of
subclinical rejection, better long-term outcomes, and an improved
quality of life.
Humana will cover the TruGraf
test for its Medicare Advantage, Medicare HMO, Medicare Network
PFFS, Medicare POS, and Medicare PPO patients.
TGI is very pleased that
Humana has extended in-network coverage for TruGraf, making this
test available to its Medicare transplant patient population. TGI
is committed to working in partnership with medical providers to
make our non-invasive approach to improving transplant outcomes
available to patients who can benefit from it.
About Transplant Genomics, Inc.
Eurofins Transplant Genomics, Inc. ("TGI") is a personalized
diagnostics company committed to improving organ transplant
outcomes worldwide through innovative tests that detect early signs
of graft injury, differentiate among actionable causes, and enable
the optimization of therapy. Working alongside the transplant
community and within the Eurofins family of companies, TGI is
commercializing a suite of tests enabling diagnoses and prediction
of transplant recipient immune status. Our flagship product is
TruGraf, the only non-invasive blood test approved by CMS that
offers the earliest possible detection of "silent" subclinical
acute rejection in kidney transplant recipients with stable graft
function. Test services are offered through TGI's CLIA laboratory
in Fremont, CA. TGI was acquired by Eurofins Scientific in
2019.
Learn more about Transplant Genomics at https://trugraf.com/
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing and
in agroscience Contract Research Organisation services. Eurofins is
one of the market leaders in certain testing and laboratory
services for genomics, discovery pharmacology, forensics, advanced
material sciences and in the support of clinical studies, as well
as having an emerging global presence in Contract Development and
Manufacturing Organisations. The Group also has a rapidly
developing presence in highly specialised and molecular clinical
diagnostic testing and in-vitro diagnostic products.
With over 50,000 staff across a decentralised and
entrepreneurial network of more than 800 laboratories in over 50
countries, Eurofins offers a portfolio of over 200,000 analytical
methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of
products, as well as providing innovative clinical diagnostic
testing services and in-vitro diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020, Eurofins reacted quickly to meet the global challenge
of COVID-19, by creating the capacity to help over 20 million
patients monthly who may have been impacted by the pandemic with
our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 25 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments during
COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005622/en/
For more information, please visit www.eurofins.com or
contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Grafico Azioni Eurofins Scientific (EU:ERF)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Eurofins Scientific (EU:ERF)
Storico
Da Mag 2023 a Mag 2024